Somewhere in a hospital’s server room right now, an ICU monitor is quietly streaming patient vitals onto the same network that runs the billing system, the pharmacy inventory, and the admin’s inbox. None of that was designed with an attacker in mind. It was designed for uptime, for convenience, for getting a diagnostic report from the lab to the doctor’s screen in seconds. That same interconnectedness is exactly why healthcare and pharma have quietly become the sector attackers go after first, not last.
This isn’t a hypothetical risk anymore. It’s a documented, measurable trend, and any conversation about pharma cybersecurity in 2026 has to start with why this sector specifically, and not banking or e-commerce, has become such fertile ground for attackers.
The Numbers Tell Their Own Story
According to Seqrite Labs’ India Cyber Threat Report 2026, built from telemetry across more than 8 million endpoints, healthcare and pharmaceuticals alone accounted for 3.79 million threat detections between October 2024 and September 2025, roughly 14% of all detections nationally. Combined with education and manufacturing, these three sectors made up nearly half of every cyber incident recorded in the country over that period.
What’s notable isn’t just the volume. It’s the nature of the attacks. Trojans and file infectors made up close to 70% of the activity, but the report also flagged something more targeted: remote access trojans and loader-based malware specifically aimed at pharmaceutical R&D systems and clinical trial data. That’s not opportunistic scanning. That’s reconnaissance aimed at intellectual property, the kind of data that takes years and crores of rupees to generate and seconds to exfiltrate.
Ransomware told a similar story from a different angle. It accounted for less than 1% of total detections but caused disproportionate damage, with incidents peaking in January 2025 alone. When one of the country’s larger pharmaceutical manufacturers disclosed a cybersecurity incident to stock exchanges, a ransomware group later claimed responsibility and published stolen data. It’s a reminder that this isn’t a theoretical risk sitting in an analyst’s report. It’s happening to companies whose names are on the shelf at every chemist in the country.
What Makes Pharma and Healthcare Such Attractive Targets
Data That Can Never Be Reset
Here’s where things get interesting from a risk perspective. A stolen credit card digit can be cancelled and reissued within a day. A compromised medical record cannot. Diagnostic histories, prescription patterns, genetic data, and clinical trial results are permanent, which means the value of that data to an attacker, whether for blackmail, insurance fraud, or resale on dark web markets, doesn’t depreciate the way financial data does. This single fact changes the entire risk calculation for healthcare cybersecurity, because there’s no equivalent of a card reissue once patient data is out.
Operational Technology That Was Never Meant to Face the Internet
Infusion pumps, imaging machines, and hospital information systems were largely built for clinical function, not adversarial environments. Many run on legacy operating systems that can’t be patched without risking the device’s medical certification. Attackers know this. Exploiting a decade-old vulnerability in an internet-connected imaging system is often easier than breaching a modern, actively maintained IT environment.
Intellectual Property Worth Stealing
For pharmaceutical companies, R&D data on novel drug formulations, biosimilars, and vaccine research represents years of investment. In our experience with organisations in this space, IP theft is often the real objective behind what looks, on the surface, like a routine ransomware incident. The ransomware is often the visible symptom. The quiet exfiltration that happened before it is the real event.
A Sprawling, Uneven Attack Surface
A single hospital network typically connects diagnostic labs, insurance processors, pharmacy systems, and third-party vendors, each with different security maturity. Most people don’t realise the weakest link is rarely the hospital’s core system. It’s usually a smaller vendor or a legacy device sitting somewhere in that chain, exploited as an entry point into a much larger network.
Where DPDP Compliance Raises the Stakes
Under the DPDP Act, healthcare organisations, including hospitals, diagnostic chains, insurers, and health-tech platforms, are classified as Data Fiduciaries. That classification carries real obligations: lawful processing, purpose limitation, explicit consent, and safeguards across every touchpoint where patient data moves, from admission records to teleconsultation logs.
For an industry already managing the operational chaos of a live breach, DPDP compliance adds a second, parallel pressure. A breach isn’t just a security failure anymore. It’s a potential regulatory event, with reporting obligations and penalty exposure attached. Organisations that treat pharma data security purely as an IT problem, separate from their compliance obligations, will find that separation increasingly costly.
What Effective Pharma and Healthcare Cybersecurity Actually Looks Like
Building real resilience in this sector isn’t about a single tool or a one-time audit. It typically involves:
- Network segmentation that keeps clinical devices, administrative systems, and third-party vendor access on genuinely separate paths, so a compromise in one doesn’t cascade into the rest
- Regular vulnerability assessments specifically covering internet-connected medical devices, not just standard IT infrastructure.
- Phishing-resistant access controls, given how consistently phishing and impersonation of bodies like ICMR or CDSCO show up as an entry vector
- Incident response plans built around clinical continuity, so a ransomware event doesn’t force a hospital back to paper records mid-treatment
- Data mapping aligned to DPDP obligations, so the organisation actually knows where patient and research data lives before a regulator, or an attacker
The Bottom Line
Pharma and healthcare in India aren’t targeted because they’re careless. They’re targeted because they sit at the intersection of high-value data, legacy infrastructure, and an attack surface that keeps expanding faster than most security budgets do. Organisations that manage this well treat cybersecurity and data compliance as a single, connected discipline rather than two separate line items.
As a cybersecurity company in India working closely with healthcare and pharmaceutical organisations, we’ve seen firsthand how much difference a properly mapped, DPDP-aligned security posture makes when an incident does happen. If your organisation hasn’t stress-tested where its clinical, research, and vendor networks actually stand, that’s a conversation worth having with Everence before an attacker forces it.